Final Results of a Phase 2, Open-Label Study of Indisulam, Idarubicin, and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Cancer - United States
doi 10.1002/cncr.31398
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Idarubicin, Cytarabine and Pravastatin as Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

Phase I Trial of SAR103168, a Novel Multi-Kinase Inhibitor, in Patients With Refractory/Relapsed Acute Leukemia or High-Risk Myelodysplastic Syndrome

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2014English

High Dose Cytarabine Plus Gemtuzumab Ozogamicin for Patients With Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902

Leukemia Research
Cancer ResearchOncologyHematology
2011English

Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

A Phase II Study of AZD2171 (Cediranib) in the Treatment of Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2014English

A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients With Relapsed/Refractory Acute Myeloid Leukemia

Advances in Hematology
Hematology
2017English

Low Dose Cytarabine and Cladribine for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Clinical Experience

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2016English

Enduring Efficacy and Tolerability of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma ( GEN 503): Final Results of an Open‐label, Phase 1/2 Study

British Journal of Haematology
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy